Falini B, Bolognesi A, Flenghi L, Tazzari P L, Broe M K, Stein H, Dürkop H, Aversa F, Corneli P, Pizzolo G
Institute of Haematology, University of Perugia, Italy.
Lancet. 1992 May 16;339(8803):1195-6. doi: 10.1016/0140-6736(92)91135-u.
In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to greater than 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.
在霍奇金病中，霍奇金和里德-施特恩贝格细胞持续表达抗原CD30。我们研究了一种免疫毒素的潜在治疗作用，该免疫毒素通过将抗CD30单克隆抗体（Ber-H2）与Ⅰ型核糖体失活蛋白皂草素（SO6）共价连接制备而成。给4例晚期难治性霍奇金病患者使用该免疫毒素（0.8mg/kg，分1或2次给药）。其中3例患者的肿瘤块迅速大幅缩小（50%至大于75%）。临床反应是短暂的（6 - 10周）。免疫组化显示两名患者体内免疫毒素与肿瘤细胞结合。所有患者均产生了针对免疫毒素两部分的抗体。
